Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

NCT02339324 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Pembrolizumab and high dose interferon alfa-2b (HDI)

Sponsor

Yana Najjar

Collaborators

[object Object]